Health ❯ Diabetes ❯ Type 2 Diabetes

Medications

GLP-1 Receptor Agonists Ozempic Semaglutide Mounjaro Semaglutida Tirzepatide FDA Approval Ozempic and Mounjaro Orforglipron Sémaglutide GLP-1 Therapy Hormonal Treatments GLP-1 Drugs Weight Management GLP-1 Agonists Incretins GLP-1 Tirzepatida GLP-1 Injections Retatrutide Insulin Production Clinical Trials Extensior

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

Prospective studies are needed to test whether the drugs directly affect chemosensory nerves.

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

Resalis’ miR-22 Antisense Shows Durable Fat Loss in Animals as Phase 1 Trial Continues

GLP-1 Drugs Linked to Lower Overall Cancer Risk in JAMA Oncology Analysis